DevvStream

Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

10 January 2023

Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre-Investigational new drug meeting.

Sign Up To Get Daily Green Stock News In Your Inbox

Please review our Disclaimer and Privacy Policy before subscribing.

STOCK QUOTE

FEATURED GREEN STOCK

GreenPower Motor

GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...

CLICK TO LEARN MORE

FEATURED GREEN STOCK

Hillcrest Energy Technologies

Hillcrest Energy Technologies is a clean technology company developing high value, high performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS